The progress of the soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation

被引：5
|
作者：
Liu, Jia-Hui [1 ]
Han, Qian-Feng [1 ]
Mo, De-Gang [1 ]
机构：
[1] Shandong First Med Univ, Liaocheng Peoples Hosp, Dept Cardiol, Liaocheng 252000, Shandong, Peoples R China
来源：
JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY | 2022年 / 65卷 / 03期
关键词：
D O I：
10.1007/s10840-022-01346-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [1] The progress of the soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation
    Jia-Hui Liu
    Qian-Feng Han
    De-Gang Mo
    Journal of Interventional Cardiac Electrophysiology, 2022, 65 : 591 - 592
  • [2] Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
    Hildenbrand, Florian F.
    Illi, Barbara
    von Felten, Stefanie
    Bachofner, Jacqueline
    Gawinecka, Joanna
    von Eckardstein, Arnold
    Mullhaupt, Beat
    Mertens, Joachim C.
    Blumel, Sena
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [3] Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
    Florian F. Hildenbrand
    Barbara Illi
    Stefanie von Felten
    Jacqueline Bachofner
    Joanna Gawinecka
    Arnold von Eckardstein
    Beat Müllhaupt
    Joachim C. Mertens
    Sena Blümel
    BMC Gastroenterology, 24
  • [4] A meta-analysis of soluble suppression of tumorigenicity 2(sST2) and clinical outcomes in pulmonary hypertension
    King Sum Luk
    Christina Ip
    MengQi GONG
    Sunny Hei WONG
    William KK Wu
    Mei DONG
    GuangPing LI
    Ka Pang Chan
    YiMei DU
    Tong LIU
    Martin CS Wong
    David Shu Cheong Hui
    Gary Tse
    Journal of Geriatric Cardiology, 2017, 14 (12) : 766 - 771
  • [5] Dowe need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2)
    Maisel, Alan S.
    Di Somma, Salvatore
    EUROPEAN HEART JOURNAL, 2017, 38 (30) : 2325 - 2332A
  • [6] A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension
    Luk, King Sum
    Ip, Christina
    Gong, Meng-Qi
    Wong, Sunny Hei
    Wu, William K. K.
    Dong, Mei
    Li, Guang-Ping
    Chan, Ka Pang
    Du, Yi-Mei
    Liu, Tong
    Wong, Martin C. S.
    Hui, David Shu Cheong
    Tse, Gary
    JOURNAL OF GERIATRIC CARDIOLOGY, 2017, 14 (12) : 766 - 771
  • [7] Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups
    Nah, Eun-Hee
    Cho, Seon
    Kim, Suyoung
    Cho, Han-Ik
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (11)
  • [8] Soluble Suppression of Tumorigenicity-2 (sst2) Predicts Mortality and Right Heart Failure in Lvad Patients
    Numan, L.
    Aarts, E.
    Ramjankhan, F.
    Van der Meer, M. G.
    Oerlemans, M.
    De Jonge, N.
    Oppelaar, A.
    Kemperman, H.
    Asselbergs, F.
    Van Laake, L. W.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S364 - S365
  • [9] IL-33 (Interleukin 33)/sST2 (Soluble Suppression of Tumorigenicity 2) Axis in Hypertension and Heart Failure
    Ghali, Rana
    Altara, Raffaele
    Louch, William E.
    Cataliotti, Alessandro
    Mallat, Ziad
    Kaplan, Abdullah
    Zouein, Fouad A.
    Booz, George W.
    HYPERTENSION, 2018, 72 (04) : 818 - 828
  • [10] The Continuation of Trickle-Down Medicine: Soluble Suppression of Tumorigenicity-2 (sST2) in Pediatric Heart Failure
    Greenway, Steven C.
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (06) : 692 - 693
12345